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the Medicare prescription drug program provided this vulnerable
population with an important new source of drug coverage.
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OBJECTIVE: Drug-drug interactions (DDI) have been well asso-
ciated with signiﬁcant medical, safety, and economic conse-
quences, particularly in older and chronically ill patients. This
study examined several aspects of medication safety by quanti-
fying and proﬁling the prevalence, population exposure, and
characteristics of clinically signiﬁcant DDIs among Medicare
Part D utilizing beneﬁciaries. Lumetra and six California Medi-
care Advantage prescription drug plans (MAPD) and stand-alone
prescription drug plans (PDP) will collaboratively utilize results
to design effective quality improvement initiatives to minimize
adverse clinical outcomes due to these DDI’s. METHODS: This
study assessed the prevalence and population exposure of DDIs
among Medicare and dual eligible (i.e., Medicare +Medi-caid
status) beneﬁciaries enrolled across six of California’s Part D
MAPD and PDPs. Retrospective, cross sectional pharmacy
claims data from January 1, 2006 through December 31, 2006
were analyzed to obtain the frequency of drug interactions that
are clinically signiﬁcant and well-documented in the medical and
pharmacy literature. RESULTS: The analysis included 368,607
utilizing beneﬁciaries. The overall prevalence rate of DDI was
5.9%. The number of clinically signiﬁcant DDI cases was 7962
per 100,000 beneﬁciaries. Stratiﬁed analyses indicated that males
and older beneﬁciaries appear to be at a higher risk of incurring
a clinically signiﬁcant DDI. Risk of a DDI also increased as the
number of unique medications and/or number of prescribing
physicians increased per enrollee. CONCLUSION: The preva-
lence and characteristics of clinically signiﬁcant DDIs among
California elderly and chronically ill patients were positively
associated with certain demographic factors and health care
resource utilization proﬁles. Stratifying high-risk individuals with
discrete or multiple DDI’s will enable Part D MAPDs and PDPs
to perform in-depth case management in targeted individuals.
Point-of-service edits and information obtained from retrospec-
tive drug claims review can be used in conjunction to customize
meaningful intervention strategies.
PHP22
MEDICARE SPENDING GROWTH FOR DIAGNOSTIC IMAGING
AND ACCESSTO CARE
Lee DW
GE Healthcare,Waukesha,WI, USA
OBJECTIVE: To measure the impact of improvements in access
to care on Medicare spending growth for diagnostic imaging (DI)
services. METHODS: We modeled Medicare DI spending growth
as a function of growth in: enrollment; per-service payment;
access to care (% using  1 service); volume (services/user); and
intensity (relative value units per service used). We then used
Medicare Standard Analytic File 5% sample data from 2002–
2005 to decompose DI spending growth into these factors by
modality: standard (x-ray and ultrasound); and advanced (com-
puted tomography (CT), magnetic resonance (MR) and nuclear).
RESULTS: Aggregate DI service spending grew at an annual rate
of 15.2% during 2002–2005, and varied substantially by modal-
ity (x-ray 10.2%, ultrasound 11.7%, CT 19.6%, MR 18.5%,
nuclear 15.0%). Enrollment growth accounted for less than 15%
of this increase (range: 7.2% (CT)—13.3% (x-ray)), while the
impact of payment increases was far greater and varied widely
(range: 7.6% (nuclear)—54.0% (x-ray)). The share of DI spend-
ing growth attributable to improvements in access to care was:
x-ray (6.5%); ultrasound (19.1%); CT (30.4%); MR (49.0%);
and nuclear (30.5%). The contribution of volume growth to
overall spending growth ranged from 10.5% for MR to 24.1%
for CT. Service intensity growth accounted for less than 10% of
spending growth for x-ray, CT and MR; 17.9% and 33.0% of
spending growth for ultrasound and nuclear were due to service
intensity growth, respectively. CONCLUSION: Improved access
to care explains approximately 30%–50% of the growth in
Medicare spending for advanced diagnostic imaging services.
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OBJECTIVE: In early 2006, 18,820 vulnerable Medicare beneﬁ-
ciaries with RA or MS participating in a biologic drug demon-
stration program (MRDD) transitioned into Medicare Part D
plans. We compared the types of biologic drug coverage offered
by Part D plans. METHODS: We examined Part D plans’ cost
structure (e.g. premium, deductible, cost sharing) for the spe-
cialty biologic drugs offered during the MRDD: adalimumab,
etanercept, anakinra (for RA), interferon beta 1a and 1b, glati-
ramer acetate, and HP acthar gel (for MS). For MRDD and Part
D plans, we compared beneﬁciaries’ average out-of-pocket costs
(OOPC). RESULTS: Beneﬁciaries enrolled in 1061 stand-alone
(SA) and 705 Medicare Advantage (MA) Part D plans. All SA
plans and all but one MA plan covered etanercept, interferon
beta 1b, and glatiramer acetate. The proportion covering the
other drugs varied between 38–92%. MA plans were more likely
to cover anakinra, interferon beta 1a, and HP acthar gel than SA
plans (p < 0.05). All plans used co-insurance as the preferred
form of cost sharing; average co-insurance ranged from 25–31%
of the drug price. The majority of plans assumed >75% of the
cost sharing for each drug dispensing during the initial coverage
period, but only 2% of plans offered coverage during the cover-
age gap. On average, beneﬁciaries’ OOPC were greater under
Part D than the standard beneﬁt-structured MRDD. Patients
with a MRDD subsidy were signiﬁcantly less likely to receive a
Part D subsidy (p < 0.0001), because assets were considered in
addition to income in the granting of subsidies under Part D.
CONCLUSION: Many Part D plans assume some costs for
specialty biologic drugs to treat RA and MS. Beneﬁciaries still
ﬁnd themselves facing high OOPC due to drug price, plans’
preference for co-insurance, and scant coverage during the
coverage gap.
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OBJECTIVE: When private payers implement changes to control
health beneﬁt costs, the longer term consequences may not be
considered. The aim was to identify scientiﬁc studies that exam-
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